Disc Medicine, Inc.
discmedicine.comWhat Do They Do?
Develops experimental treatments that alter heme and iron pathways for patients with blood diseases, including porphyrias, anemia and disorders involving excess red blood cells.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 30, 2026
−$59.5MView ↗
- ▲ +8% (Loss)
- vs −$55.2M in Q2 FY2025
Treatment targets
The older report named chronic kidney disease anemia and Diamond-Blackfan anemia among its targets; the latest report names inflammatory bowel disease anemia and sickle cell disease among its current targets.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for…View ↗
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for…View ↗
Who Do They Compete With?
Competes with Agios Pharmaceuticals, Akebia Therapeutics, Amgen, Astellas Pharma, Bristol-Myers Squibb, FibroGen, GlaxoSmithKline, Incyte, Ono Pharmaceuticals, Keros Therapeutics, Merck &, Otsuka Pharmaceutical, and Vifor Pharma
10-K for FY2025, filed Feb 26, 2026We face competition more specifically from companies that discover, develop, and market therapies for the treatment of hematologic…View ↗
Loading...
